• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet “bets big” on Massachusetts with new manufacturing facility in Acton

September 29, 2017 By Sarah Faulkner

Insulet's new manufacturing site in ActonInsulet (NSDQ:PODD) broke ground at its new manufacturing facility in Acton, Mass. yesterday, hosting a ceremony that featured the state’s governor, Charlie Baker, members of Baker’s administration and a young “Podder” named Lexi Bentinganan.

Diagnosed at age 7 with Type I diabetes, Lexi has been using Insulet’s tubeless insulin delivery device, the Omnipod, since 2013.

“It has given me complete control over my diabetes and reminded me that I’m just a normal kid,” she told the crowd of people gathered at Insulet’s 26-acre site.

The Omnipod device is currently manufactured overseas, chairman & CEO Patrick Sullivan said. The 300,000 square-foot site will help Insulet support 200,000 additional Omnipod users, according to the chief executive.

“There are many key decisions to be made in building a great and last enterprise. Few of those decisions are bigger and have higher stakes than choosing where to invest to build your company’s future,” Sullivan said. “After considering locations from coast-to-coast, we decided to bet big on the future of manufacturing in Massachusetts.”

The new firm will bring more than 1,000 jobs to Acton and result in a $100 million investment to the town over the next few years, he added. The facility is slated to include multiple new manufacturing lines and an innovation center.

“The statement this makes about the commonwealth is an important one,” Baker said. “It says, yet again, that this is a state that deserves its ranking as the number one place to live and raise a family…that this is, in fact, the number one innovation state in the country, according to Bloomberg News, and that this is, in fact, a truly wonderful place to start and build a technology company and a healthcare organization.”

“Today Omnipod helps a person get more discrete, more precise delivery of insulin,” president & COO Shacey Petrovic added. “Tomorrow, Omnipod will do this and so much more.”

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Insulet

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS